Wuhan Thalys Med Tech Co Ltd (603716) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.052x

Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥54.57 Million ≈ $7.99 Million USD) by net assets (CN¥1.05 Billion ≈ $154.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 603716 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Wuhan Thalys Med Tech Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Wuhan Thalys Med Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Wuhan Thalys Med Tech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
OPTHEA LTD (SP.ADR/8) F:UKJ2	N/A
Sichuan Kexin Mechanic Electric SHE:300092	0.018x
Greenlight Capital Re Ltd NASDAQ:GLRE	0.050x
Korea Electric Terminal KO:025540	0.052x
Zhejiang Huakang Pharmaceutical Co Ltd SHG:605077	N/A
Hefei Lifeon Pharmaceutical Co Ltd SHE:003020	0.336x
Surfilter Network Technology Co Ltd SHE:300311	0.007x
Kearny Financial Corp NASDAQ:KRNY	0.019x

Annual Cash Flow Conversion Efficiency for Wuhan Thalys Med Tech Co Ltd (2011–2025)

The table below shows the annual cash flow conversion efficiency of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Wuhan Thalys Med Tech Co Ltd (603716) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥904.49 Million ≈ $132.35 Million	CN¥-37.75 Million ≈ $-5.52 Million	-0.042x	-140.32%
2024-12-31	CN¥962.04 Million ≈ $140.78 Million	CN¥99.60 Million ≈ $14.57 Million	0.104x	+8.12%
2023-12-31	CN¥1.31 Billion ≈ $192.38 Million	CN¥125.89 Million ≈ $18.42 Million	0.096x	+409.71%
2022-12-31	CN¥1.50 Billion ≈ $219.05 Million	CN¥28.12 Million ≈ $4.12 Million	0.019x	+124.52%
2021-12-31	CN¥1.74 Billion ≈ $255.04 Million	CN¥-133.52 Million ≈ $-19.54 Million	-0.077x	-1488.68%
2020-12-31	CN¥1.80 Billion ≈ $263.77 Million	CN¥9.94 Million ≈ $1.46 Million	0.006x	-90.48%
2019-12-31	CN¥1.62 Billion ≈ $237.21 Million	CN¥93.92 Million ≈ $13.74 Million	0.058x	+247.56%
2018-12-31	CN¥1.63 Billion ≈ $237.88 Million	CN¥-63.83 Million ≈ $-9.34 Million	-0.039x	+37.69%
2017-12-31	CN¥1.00 Billion ≈ $146.88 Million	CN¥-63.25 Million ≈ $-9.26 Million	-0.063x	-218.21%
2016-12-31	CN¥859.29 Million ≈ $125.74 Million	CN¥-17.02 Million ≈ $-2.49 Million	-0.020x	-120.20%
2015-12-31	CN¥470.30 Million ≈ $68.82 Million	CN¥46.11 Million ≈ $6.75 Million	0.098x	+32.39%
2014-12-31	CN¥405.99 Million ≈ $59.41 Million	CN¥30.07 Million ≈ $4.40 Million	0.074x	-21.25%
2013-12-31	CN¥345.97 Million ≈ $50.63 Million	CN¥32.54 Million ≈ $4.76 Million	0.094x	+933.02%
2012-12-31	CN¥296.50 Million ≈ $43.39 Million	CN¥2.70 Million ≈ $394.98K	0.009x	+109.55%
2011-12-31	CN¥253.90 Million ≈ $37.15 Million	CN¥-24.22 Million ≈ $-3.54 Million	-0.095x	--

About Wuhan Thalys Med Tech Co Ltd

SHG:603716 China Diagnostics & Research

Market Cap

$512.79 Million

CN¥3.50 Billion CNY

Market Cap Rank

#12259 Global

#3575 in China

Share Price

CN¥15.52

Change (1 day)

-1.15%

52-Week Range

CN¥12.15 - CN¥36.40

All Time High

CN¥45.48